DotBio

About:

DotBio develops multi-functional antibodies based on its proprietary DotBody technology as the next generation of cancer therapies.

Website: https://www.dotbiopharma.com/

Top Investors: Gaorong Capital, Enterprise Singapore, Prox Ventures, AIM-HI Accelerator Fund

Description:

DotBio develops multi-functional antibodies based on its proprietary DotBody technology as the next generation of cancer therapies. DotBio develops antibody therapies that target, at multiple junctions, the interplay between tumors and the tumor microenvironment to re-establish an effective immune response. Our proprietary technologies enable the ­rapid generation of multi-specific antibodies targeting multiple processes. The rapid testing of combinatorial ensembles of multi-specific antibody prototypes can directly identify molecules re-activating the tumor immune response with novel synergistic mechanisms.